1. Home
  2. RPID vs MIST Comparison

RPID vs MIST Comparison

Compare RPID & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPID
  • MIST
  • Stock Information
  • Founded
  • RPID 2006
  • MIST 2003
  • Country
  • RPID United States
  • MIST Canada
  • Employees
  • RPID N/A
  • MIST N/A
  • Industry
  • RPID Medical Specialities
  • MIST Biotechnology: Pharmaceutical Preparations
  • Sector
  • RPID Health Care
  • MIST Health Care
  • Exchange
  • RPID Nasdaq
  • MIST Nasdaq
  • Market Cap
  • RPID N/A
  • MIST 98.1M
  • IPO Year
  • RPID 2021
  • MIST N/A
  • Fundamental
  • Price
  • RPID $2.68
  • MIST $0.88
  • Analyst Decision
  • RPID Buy
  • MIST Strong Buy
  • Analyst Count
  • RPID 1
  • MIST 2
  • Target Price
  • RPID $8.00
  • MIST $17.00
  • AVG Volume (30 Days)
  • RPID 358.4K
  • MIST 4.5M
  • Earning Date
  • RPID 05-02-2025
  • MIST 03-13-2025
  • Dividend Yield
  • RPID N/A
  • MIST N/A
  • EPS Growth
  • RPID N/A
  • MIST N/A
  • EPS
  • RPID N/A
  • MIST N/A
  • Revenue
  • RPID $28,051,000.00
  • MIST N/A
  • Revenue This Year
  • RPID $16.97
  • MIST N/A
  • Revenue Next Year
  • RPID $24.66
  • MIST $1,105.43
  • P/E Ratio
  • RPID N/A
  • MIST N/A
  • Revenue Growth
  • RPID 24.57
  • MIST N/A
  • 52 Week Low
  • RPID $0.58
  • MIST $0.75
  • 52 Week High
  • RPID $4.04
  • MIST $2.75
  • Technical
  • Relative Strength Index (RSI)
  • RPID 53.57
  • MIST 30.59
  • Support Level
  • RPID $2.40
  • MIST $1.86
  • Resistance Level
  • RPID $2.80
  • MIST $2.36
  • Average True Range (ATR)
  • RPID 0.25
  • MIST 0.23
  • MACD
  • RPID 0.02
  • MIST -0.06
  • Stochastic Oscillator
  • RPID 83.45
  • MIST 7.43

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Share on Social Networks: